(Q37038999)

17 August 2017

1 reference

title

Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain (English)

1 reference

17 August 2017

1 reference

Mellar P Davis

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

17

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

85-95

1 reference

The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

A historical overview of chemical research on cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoid pharmacology: the first 66 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoid physiology and pharmacology: 30 years of progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

The effects of cannabinoids on the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Functional characteristics of the midbrain periaqueductal gray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Neuroanatomy of the pain system and of the pathways that modulate pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Presynaptic specificity of endocannabinoid signaling in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

The molecular logic of endocannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Identification of cannabinoid receptors in cultures of rat cerebellar granule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Pharmacokinetics and pharmacodynamics of cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

The acute effects of cannabinoids on memory in humans: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Recent advances in the metabolism of cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Antagonism of marihuana effects by indomethacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Transdermal nicotine alters some of marihuana's effects in male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Nabilone: an alternative antiemetic for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Clinical practice guidelines on antiemetics in oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

A Retrospective Chart Review of the Use of Olanzapine for the Prevention of Delayed Emesis in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Emerging drugs for chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoids for pain and nausea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Experience with the synthetic cannabinoid nabilone in chronic noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Effects of nabilone, a synthetic cannabinoid, on postoperative pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

EFNS guidelines on pharmacological treatment of neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Algorithm for neuropathic pain treatment: an evidence based proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

Different types of calcium channels mediate central synaptic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.85

21 January 2018

Identifiers

DOI

10.1517/13543784.17.1.85

1 reference

17 August 2017

1 reference